<?xml version="1.0" encoding="UTF-8"?>
<p>The kinetics and outcomes of HBVr in various immune-mediated inflammatory diseases from a wide spectrum of medical specialties were described in a French study combining physician-collected and published patients.
 <sup>
  <xref rid="bibr45-1759720X20912646" ref-type="bibr">45</xref>
 </sup> The authors included a total of 138 HBV-infected patients, most with chronic HBV infection (
 <italic>n</italic> = 99, 72%); among them, 11 (8%) had been treated with CYC and experienced HBVr. CYC-induced HBVr occurred earlier than that associated with rituximab (RTX) or tumor necrosis factor inhibitors (TNFi) (8 
 <italic>versus</italic> 13 
 <italic>versus</italic> 26 weeks, respectively, 
 <italic>p</italic> = 0.009).
</p>
